Results 201 to 210 of about 308,666 (390)
Changes in N‐terminal pro‐B‐type natriuretic peptide and assessment of clinical endpoints according to prior exposure to renin–angiotensin system inhibitors in the Pre‐specified substudy of Prospective comparison of ARNI with ARB Given following stabiLization In DEcompensated HFpEF (PARAGLIDE‐HF).
Nina Nouhravesh+14 more
wiley +1 more source
Successful Therapy of Prolonged Hypotension with an Adrenergic Beta-Receptor Blocking Agent [PDF]
Myron H. Luria+2 more
openalex +1 more source
CONTROLLED HYPOTENSION BY EXTRADURAL SPINAL BLOCK UNDER CHLORPROMAZINE COVER *
L Havers
openalex +1 more source
Abstract Guidelines for management of heart failure with reduced ejection fraction (HFrEF) emphasize personalized care, patient engagement, and shared decision‐making. Medications and cardiac rhythm management (CRM) devices are recommended with a high level of evidence. However, there are significant disparities: patients who could benefit from devices
Biykem Bozkurt+15 more
wiley +1 more source
Linking guideline‐directed medical therapy (GDMT) implementation and appropriate polypharmacy management in heart failure (HF). Polypharmacy can represent a barrier to the proper implementation of life‐prolonging GDMT for HF. A reasonable balance between the optimization of GDMT and avoiding inappropriate polypharmacy is mandatory in the contemporary ...
Davide Stolfo+27 more
wiley +1 more source
THE USE OF HYPOTENSION IN ANAESTHESIA FOR EAR, NOSE AND THROAT OPERATIONS
C.B. ANDREAE, H Griffiths
openalex +1 more source
Finerenone and glycaemic status in patients with heart failure with mildly reduced/preserved ejection fraction. CI, confidence interval; CV, cardiovascular; HF, heart failure; HR, hazard ratio; RR, rate ratio. Abstract Aims The efficacy and safety of the non‐steroidal mineralocorticoid receptor antagonist, finerenone, have not been examined in patients
Jawad H. Butt+18 more
wiley +1 more source